Predictive Value of Serum and Tissue miR-205 for Postoperative Recurrence of Ovarian-type Endometriosis
-
摘要:
目的 探讨血清及组织miR-205预测卵巢型子宫内膜异位症（EMT）术后复发价值。 方法 选取2019年6月至2021年6月石家庄市人民医院收治的100例卵巢型EMT患者，均接受腹腔镜手术，根据术后24个月复发情况分为复发组（n = 24）和未复发组（n = 76），比较2组一般资料、血清及子宫内膜组织癌抗原125（CA125）、miR-205，Spearman分析CA125与miR-205相关性，绘制受试者工作特征曲线（ROC）及曲线下面积（AUC）分析miR-205、CA125预测卵巢型EMT术后复发效能，采用DeLong检验miR-205、CA125预测卵巢型EMT术后复发AUC差异。 结果 2组一般资料比较差异无统计学意义（P > 0.05）；复发组r-AFS分期血清及子宫异位内膜组织CA125含量高于未复发组，血清及子宫异位内膜组织miR-205表达低于未复发组（P < 0.05）；卵巢型EMT术后复发患者血清及子宫内膜组织miR-205与CA125呈负相关（r = -0.728、-0.713，均P < 0.001）；ROC曲线显示，血清、子宫异位内膜组织miR-205预测卵巢型EMT术后复发的AUC为0.741、0.809。DeLong检验显示，血清、子宫异位内膜组织miR-205与CA125预测卵巢型EMT术后复发的AUC比较差异无统计学意义（Z值为0.020，P为0.951）。 结论 卵巢型EMT术后复发患者血清及子宫异位内膜组织miR-205呈低表达，与CA125呈负相关，测定血清及子宫异位内膜组织miR-205有助于提高预测效能，指导临床治疗。 Abstract:Objective To explore the predictive value of serum and tissue miR-205 for postoperative recurrence of ovarian-type endometriosis （EMT）. Methods A total of 100 patients with ovarian-type EMT who were treated at Shijiazhuang People's Hospital from June 2019 to June 2021 were selected. All patients underwent laparoscopic surgery and were divided into a recurrence group （n = 24） and a non-recurrence group （n = 76） based on their recurrence status 24 months post-surgery. The general information, serum, and endometrial tissue cancer antigen 125 （CA125）, and miR-205 levels were compared between the two groups. Spearman's correlation was used to analyze the correlation between CA125 and miR-205. Receiver operating characteristic （ROC） curves and area under the curve （AUC） were plotted to analyze the predictive efficacy of miR-205 and CA125 for postoperative recurrence of ovarian EMT. The DeLong test was used to compare the differences in AUC between miR-205 and CA125 for predicting postoperative recurrence of ovarian EMT. Results There was no significant difference in the general data between the two groups （P > 0.05）. The CA125 levels in serum and ectopic endometrial tissue of the recurrent group were higher than those in the non-recurrent group, while the expression of miR-205 in serum and ectopic endometrial tissue was lower than that in the non-recurrent group （P < 0.05）. There was a negative correlation between miR-205 and CA125 in serum and endometrial tissue of patients with ovarian EMT recurrence after surgery （r = -0.728, -0.713, both P < 0.001）. The ROC curve showed that the AUC of miR-205 in serum and ectopic endometrial tissue for predicting ovarian EMT recurrence after surgery was 0.741 and 0.809, respectively. The DeLong test showed no significant difference in the AUC of miR-205 in serum and ectopic endometrial tissue compared with CA125 for predicting ovarian EMT recurrence after surgery （Z = 0.020, P = 0.951）. Conclusion The low expression of miR-205 in serum and ectopic endometrial tissue of patients with ovarian EMT recurrence after surgery is negatively correlated with CA125. Measuring miR-205 in serum and ectopic endometrial tissue can help improve the predictive efficacy and guide clinical treatment. -
Key words:
- Endometriosis /
- Laparoscopic surgery /
- Recurrence /
- Serum /
- Endometrial tissue /
- MiR-205
-
表 1 2组一般资料比较[n（%）/（$\bar x \pm s $）]
Table 1. Comparison of general information of the 2 groups [n（%）/（$\bar x \pm s $）]
组别（n） 年龄（岁） 生育次数（次） 流产次数（次） r-AFS分期 月经周期 临床表现 Ⅲ期 Ⅳ期 分泌期 增殖期 痛经 月经异常 不孕 复发组
（n = 24）30.90±3.31 2.01±0.33 1.25±0.30 16（66.67） 8（33.33） 12（50.00） 12（50.00） 19（79.17） 9（37.50） 10（41.67） 未复发组
（n = 76）31.48±2.26 2.12±0.25 1.18±036 42（55.26） 34（44.74） 40（52.63） 36（47.37） 57（75.00） 28（36.84） 23（30.26） t/χ2 0.973 1.734 0.010 0.974 0.051 0.174 0.003 1.073 P
P0.333 0.086 0.992 0.324 0.822 0.677 0.954 0.300 
下载: 导出CSV
表 2 2组血清及子宫内膜组织miR-205、CA125表达比较（$ \bar x \pm s $）
Table 2. Comparison of miR-205 expression in serum and endometrial tissues between the two groups （$\bar x \pm s$）
组别 n miR-205 CA125 血清 在位内膜组织 异位内膜组织 血清 在位内膜组织 异位内膜组织 复发组 24 1.50±0.44 0.95±0.26 0.56±0.16 43.89±13.16 1.38±0.40 1.86±0.55 未复发组 76 2.17±0.65 0.90±0.30 0.73±0.20 30.30±9.10 1.34±0.38 1.30±0.41 t 4.712 0.734 3.794 5.691 0.444 5.353 P <0.001* 0.465 <0.001* <0.001* 0.658 <0.001* *P < 0.05。
下载: 导出CSV
表 3 血清及子宫内膜组织miR-205、CA125表达预测术后复发效能
Table 3. Serum and endometrial tissue miR-205 and CA125 expression predicts postoperative recurrence efficacy
项目 AUC（95%CI） 截断值 敏感度（%） 特异度（%） P 血清miR-205 0.741（0.644～0.823） <1.50 66.67 80.26 <0.001* 血清CA125 0.778（0.684～0.855） >41.56 70.83 85.53 <0.001* 子宫异位内膜组织miR-205 0.809（0.718～0.881） <0.61 66.67 81.58 <0.001* 子宫异位内膜组织CA125 0.819（0.729～0.889） >1.60 79.17 80.26 <0.001* *P < 0.05。
下载: 导出CSV
-
[1] Varga J,Reviczká A,Háková H,et al. Predictive factors of endometriosis progression into ovarian cancer[J]. J Ovarian Res,2022,15(1):5. doi: 10.1186/s13048-021-00940-8 [2] Amro B,Ramirez Aristondo M E,Alsuwaidi S,et al. New understanding of diagnosis,treatment and prevention of endometriosis[J]. Int J Environ Res Public Health,2022,19(11):6725. doi: 10.3390/ijerph19116725 [3] Heres C K,Rindos N B,Fulcher I R,et al. Opioid use after laparoscopic surgery for endometriosis and pelvic pain[J]. J Minim Invasive Gynecol,2022,29(12):1344-1351. doi: 10.1016/j.jmig.2022.09.013 [4] Moreno-sepulveda J,Romeral C,Niño G,et al. The effect of laparoscopic endometrioma surgery on anti-m ü llerian hormone: a systematic review of the literature and meta-analysis[J]. JBRA Assist Reprod,2022,26(1):88-104. [5] Tan Y,Flynn W F,Sivajothi S,et al. Single-cell analysis of endometriosis reveals a coordinated transcriptional programme driving immunotolerance and angiogenesis across eutopic and ectopic tissues[J]. Nat Cell Biol,2022,24(8):1306-1318. doi: 10.1038/s41556-022-00961-5 [6] 刘秋颖,李晓妍,张亚云,等. miR-205-5p,PDCD5,Beclin1在子宫内膜癌组织中的表达及相关性研究[J]. 河北医科大学学报,2022,43(7):796-800,816. doi: 10.3969/j.issn.1007-3205.2022.07.011 [7] 中国医师协会妇产科医师分会,中华医学会妇产科学分会,子宫内膜异位症协作组. 子宫内膜异位症诊治指南(第三版)[J]. 中华妇产科杂志,2021,56(12):812-824. doi: 10.3760/cma.j.cn112141-20211018-00603 [8] 贺艳丽,王运萍,葛俊丽,等. 血清MMIF,HE4联合检测对子宫内膜异位症患者r-AFS分期及痛经程度的预测价值[J]. 海南医学,2023,34(7):966-969. doi: 10.3969/j.issn.1003-6350.2023.07.013 [9] 孙利娟,李涛,张琼. 腹腔镜术后醋酸戈舍瑞林缓释植入剂治疗卵巢型子宫内膜异位症临床疗效及术后复发相关因素分析[J]. 中国计划生育学杂志,2022,30(11):2537-2542. [10] Hermens M,van Altena A M,Bulten J,et al. Increased incidence of ovarian cancer in both endometriosis and adenomyosis[J]. Gynecol Oncol,2021,162(3):735-740. doi: 10.1016/j.ygyno.2021.07.006 [11] Krämer B,Andress J,Neis F,et al. Adhesion prevention after endometriosis surgery - results of a randomized,controlled clinical trial with second-look laparoscopy[J]. Langenbecks Arch Surg,2021,406(6):2133-2143. doi: 10.1007/s00423-021-02193-x [12] 胡来花,陈艳,周颖,等. Ⅲ~Ⅳ期子宫内膜异位症术后复发相关因素的研究[J]. 国际妇产科学杂志,2021,48(3):2. [13] Zakhari A,Delpero E,Mckeown S,et al. Endometriosis recurrence following post-operative hormonal suppression: A systematic review and meta-analysis[J]. Hum Reprod Update,2021,27(1):96-107. doi: 10.1093/humupd/dmaa033 [14] Scioscia M,Zanetti I,Raspanti X,et al. Ultrasound differential diagnosis in deep infiltrating endometriosis of the urinary tract[J]. J Ultrasound Med,2020,39(11):2261-2275. doi: 10.1002/jum.15322 [15] Sakala M D,Jha P,Tong A,et al. MR imaging of endometriosis of the adnexa[J]. Magn Reson Imaging Clin N Am,2023,31(1):121-135. doi: 10.1016/j.mric.2022.06.006 [16] 花霞,朱青蓝,蒋叶舟. 子宫内膜异位症患者血清CA125和HE4表达水平与抗核抗体定量的相关性分析[J]. 河北医药,2022,44(14):2195-2197. doi: 10.3969/j.issn.1002-7386.2022.14.028 [17] 钱燕,晋茂生,叶国柳. 血清CA125,hs-CRP及NLR与盆腔子宫内膜异位症分期的相关性及对其诊断的预测价值[J]. 中国医药导报,2022,19(35):84-87. [18] 秦洁. r-AFS分期评分联合术前血清IL-6和CA125水平对子宫内膜异位症患者腹腔镜保守性手术后复发的预测价值[J]. 临床与病理杂志,2023,43(1):55-61. doi: 10.3978/j.issn.2095-6959.2023.221259 [19] Raja M H R,Farooqui N,Zuberi N,et al. Endometriosis,infertility and microRNA's: A review[J]. J Gynecol Obstet Hum Reprod,2021,50(9):102157. doi: 10.1016/j.jogoh.2021.102157 [20] Kumar V,Pandey A,Arora A,et al. Diagnostics and therapeutic potential of mir-205 and mir-34a in ovarian cancer management: A miRNA-target-based analysis[J]. DNA Cell Biol,2023,42(3):151-162. doi: 10.1089/dna.2022.0487 [21] 李智永,杜太平,陈颢,等. 微小RNA-205靶向调控单羧酸转运蛋白1对结直肠癌细胞乳酸水平和增殖能力的影响[J]. 中华实验外科杂志,2021,38(6):1086-1089. doi: 10.3760/cma.j.cn421213-20201029-01399 [22] 王雪娟,宋玉霞,崔培林,等. miR-205在卵巢子宫内膜异位症患者内膜组织中的表达及对VEGFA的影响[J]. 河北医药,2022,44(18):2783-2786. doi: 10.3969/j.issn.1002-7386.2022.18.015 [23] 李娜,张永. 桂枝茯苓胶囊治疗子宫内膜异位症及对患者血清Flk-1,COX-2,VEGF,PGE2水平的影响[J]. 中国计划生育学杂志,2022,30(9):1977-1982. [24] 雷玉荣,刘宇,陈玉花,等. 辛伐他汀辅助治疗对子宫内膜异位症术后患者氧化应激状态及IGF-1,VEGF水平的影响[J]. 疑难病杂志,2022,21(10):1058-1062. [25] 郭鑫,林曼霞,旦慧文,等. 血清VEGF-A,sHLA-G,Syndecan-1水平与子宫内膜异位症患者疾病分期和痛经程度的相关性及其联合检测的诊断价值研究[J]. 现代生物医学进展,2022,22(20):3892-3896. [26] 闵逸飞,应小燕. miR-205-5p负靶向调控血管内皮生长因子A对子宫内膜异位症的影响[J]. 东南国防医药,2022,24(6):561-568. -
点击查看大图
图(1) / 表(3)
计量
- 文章访问数: 130
- HTML全文浏览量: 105
- PDF下载量: 1
- 被引次数: 0
